Navigation Links
Lilly Reports Third-Quarter 2011 Results
Date:10/20/2011

e mid-single digits. The company still anticipates that the impact of U.S. health care reform will lower 2011 revenue by $400 million to $500 million. 2011 revenue guidance assumes rapid and severe erosion of global Zyprexa sales after patent expirations in major markets, including the U.S. starting in October 2011, and the continued erosion of U.S. Gemzar sales. The company expects these reductions in revenue to be offset by sales growth of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.

The company still anticipates that gross margin as a percent of revenue will decline between 2 and 3 percentage points.

Marketing, selling and administrative expenses are still projected to grow in the high-single digits and still include an estimated $150 million to $200 million in non-tax deductible expense for the mandatory pharmaceutical manufacturers fee associated with U.S. health care reform. Research and development expense growth is still projected to be in the low single digits.

Other income is now expected to be a net expense of between $175 million and $225 million.

The tax rate is now expected to be approximately 20 percent on a non-GAAP basis and approximately 19.5 percent on a reported basis.

Cash flows are still expected to be sufficient to fund capital expenditures that are now expected to be approximately $700 million, as well as anticipated business development activity and the company's dividend.

Webcast of Conference Call

As previously announced, investors and the general public can access a live webcast of the third-quarter 2011 financial results conference call through a link on Lilly's website at www.investor.lilly.com. The conference call will be held today from 9:00 a.m. to 10:00 a.m. Eastern Daylight Time (EDT) and will be available for replay via the website through November 18, 2011.

Lilly, a leading innovation-driven corporation, is devel
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Lilly Declares Fourth-Quarter 2011 Dividend
2. Lilly Announces Changes in Senior Management
3. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
4. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
5. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
6. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
7. Lilly Health Channel Debuts on YouTube
8. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
9. The American Diabetes Association and Eli Lilly and Company Encourage African Americans to Learn About Diabetes Through a Familiar Face
10. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
11. U.S. Court of Appeals Affirms Validity of Lillys Strattera Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Drugs - Global Strategic Business Report" report to their ... for Human Growth Hormone Drugs in US$ Million by the ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... Aug. 19, 2014  Stryker Corporation,s Orthopaedics Division, the Official ... is bringing its message of joint health to golf fans ... this week at The Barclays.  The company,s fan destination ... Spectator Village near the 17 th fairway at the ... on Thursday, August 21 st .    At ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... 31, 2011 Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) has approved its ... and delivery of diagnostic, embolic and therapeutic materials ... be used by interventional radiologists for minimally invasive ...
... Endologix, Inc. (Nasdaq: ELGX ), ... announced today the publication of favorable clinical results ... of abdominal aortic aneurysm (EVAR).  The peer-reviewed article ... trial, with successful aneurysm exclusion in all patients, ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 2Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 3Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 4Endologix Announces Favorable Clinical Results for Nellix Technology 2Endologix Announces Favorable Clinical Results for Nellix Technology 3
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... 2014 "I decided that there needed ... an optimal manner without the hassles associated with using ... , The patent-pending DR. GATES ORAL-HYGIENE TOOL provides an ... It promotes good oral hygiene and fresh breath, and ... Convenient, compact, affordable, eco-friendly and easy to use, the ...
(Date:8/20/2014)... been chosen by Plymouth University to be an official ... 2009 to raise awareness of, and funding for, scientific ... tumour patients. , A range of events and activities ... charity, and members of staff and students, as well ... fundraise and volunteer. The involvement of the wider community ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... available since the middle of 2011 as a treatment ... early benefit assessment pursuant to the "Act on the ... German Institute for Quality and Efficiency in Health Care ... added benefit in comparison with the previous standard therapy. ...
... study, initiated by the Swiss researchers and published in ... in the brain. Anxiety disorders constitute a complex ... Patients suffering from such disorders fear certain situations or ... the real danger they present. The amygdala, a ...
... -- The presence of circulating tumor cells in the blood ... have just been diagnosed with inflammatory breast cancer, according to ... research shows that these stray tumor cells may signal that ... even before imaging reveals any metastases. The results will ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. ... especially starches, may boost the risk of breast cancer ... public health doctoral student at the University of California, ... carbohydrates, particularly starchy foods such as potatoes, that breast ...
... Biology (FASEB) is pleased to announce the addition of ... the Society for Pediatric Research, which will bring the ... very dynamic groups representing extremely important areas of research, ... said FASEB President Joseph C. LaManna, PhD. "We welcome ...
... a University of Notre Dame researcher, is one of the coauthors ... scientists in academia and industry that calls for strong steps to ... bacteria. The group issued a priority list of steps that need ... The paper is an outgrowth of a meeting the group ...
Cached Medicine News:Health News:Boceprevir: Indication of added benefit for specific patients 2Health News:Boceprevir: Indication of added benefit for specific patients 3Health News:The cortex plays an essential part in emotional learning 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 2Health News:Circulating tumor cells not linked to survival in newly diagnosed inflammatory breast cancer 3Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 2Health News:Starchy Foods May Boost Risk of Breast Cancer Recurrence 3Health News:New paper calls for strong steps to tackle antibiotic resistance 2
... multifunction plate reader that offers four different ... time-resolved fluorescence, high-perfomance luminescence and absorbance. The ... that deliver reagent at the point of ... can be performed easily and allowing the ...
This new dedicated VICTOR2 model is for fluorescence and luminescence measurements....
... VICTOR2 multilabel counter with ... stacker and robot loading ... density time-resolved fluorescence, luminescence ... of the instrument is ...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
Medicine Products: